Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
1998423 | Molecular Genetics and Metabolism | 2014 | 4 Pages |
Abstract
•The precise metabolic cause of the seizures in HPP remains unknown.•A curative therapy for the epilepsy of HPP is still not available.•The treatment in HPP with only seizures should be enzyme replacement therapy.
An infant carrying a heterozygous c.43_46delACTA and a heterozygous c.668 G>A mutation in the ALPL gene with hypophosphatasia in the absence of bone deformities presented with therapy-resistant seizures. Pyridoxal phosphate was extremely high in CSF and plasma. Pyridoxine treatment had only a transient effect and the severe encephalopathy was fatal. Repeated brain MRIs showed progressive cerebral damage. The precise metabolic cause of the seizures remains unknown and pyridoxine treatment apparently does not cure the epilepsy.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biochemistry
Authors
Marieke G.A. de Roo, Nico G.G.M. Abeling, Charles B. Majoie, Annet M. Bosch, Johannes H.T.M. Koelman, Jan M. Cobben, Marinus Duran, Bwee Tien Poll-The,